Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

FARMACEUTISK LABORATORIUM FERRING A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   12.8% 9.2% 10.4% 10.7% 16.7% 9.6% 14.6% 14.6%   Credit score (0-100)   19 28 23 21 10 24 15 15   Credit rating   BB BB BB BB BB BB BB BB   Credit limit (kDKK)   -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   0.0 0.0 0.0 0.0 -312 -670 0.0 0.0   EBITDA   -384 156 33.0 -381 -312 -670 0.0 0.0   EBIT   -384 156 33.0 -381 -312 -670 0.0 0.0   Pre-tax profit (PTP)   -4,898.0 152.0 31.0 -383.0 -66,786.0 -10,325.0 0.0 0.0   Net earnings   -3,820.0 119.0 24.0 -299.0 -91,647.0 -8,059.0 0.0 0.0   Pre-tax profit without non-rec. items   -4,898 152 31.0 -383 -66,786 -10,325 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   -202,443 -202,324 -202,300 -202,600 -294,246 -302,305 -303,305 -303,305   Interest-bearing liabilities   204,694 205,529 205,528 205,528 205,533 465,273 303,305 303,305   Balance sheet total (assets)   2,702 3,399 3,315 3,143 3,379 163,997 0.0 0.0   Net Debt   204,694 205,529 205,528 205,528 205,533 465,273 303,305 303,305     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   0.0 0.0 0.0 0.0 -312 -670 0.0 0.0   Gross profit growth   0.0% 0.0% 0.0% 0.0% 0.0% -114.7% 0.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,702 3,399 3,315 3,143 3,379 163,997 0 0   Balance sheet change%   -9.0% 25.8% -2.5% -5.2% 7.5% 4,753.4% -100.0% 0.0%   Added value   -384.0 156.0 33.0 -381.0 -312.0 -670.0 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 1.0 2.0 -1.0 -2.0 -3.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   0.0% 0.0% 0.0% 0.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -0.2% 0.1% 0.0% -0.2% -0.1% -0.2% 0.0% 0.0%   ROI %   -0.2% 0.1% 0.0% -0.2% -0.2% -0.2% 0.0% 0.0%   ROE %   -134.7% 3.9% 0.7% -9.3% -2,810.4% -9.6% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -98.7% -98.3% -98.4% -98.5% -98.9% -64.8% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -53,305.7% 131,749.4% 622,812.1% -53,944.4% -65,876.0% -69,443.7% 0.0% 0.0%   Gearing %   -101.1% -101.6% -101.6% -101.4% -69.9% -153.9% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   2.2% 0.0% 0.0% 0.0% 32.3% 2.9% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0   Current Ratio   0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0   Cash and cash equivalent   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 804.9 560.6 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -202,443.0 -202,324.0 -202,300.0 -202,600.0 -294,246.0 -302,305.0 -151,652.5 -151,652.5   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0